Advanced search
Add to list

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

(2009) ANNALS OF ONCOLOGY. 20(11). p.1842-1847
Author
Organization
Keywords
COMBINATION, THERAPY, OXALIPLATIN, LEUCOVORIN, FLUOROURACIL, TRIAL, PHASE-II

Citation

Please use this url to cite or link to this publication:

MLA
Van Cutsem, E et al. “Safety and Efficacy of First-line Bevacizumab with FOLFOX, XELOX, FOLFIRI and Fluoropyrimidines in Metastatic Colorectal Cancer: The BEAT Study.” ANNALS OF ONCOLOGY 20.11 (2009): 1842–1847. Print.
APA
Van Cutsem, E, Rivera, F., Berry, S., Kretzschmar, A., Michael, M., DiBartolomeo, M., Mazier, M., et al. (2009). Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. ANNALS OF ONCOLOGY, 20(11), 1842–1847.
Chicago author-date
Van Cutsem, E, F Rivera, S Berry, A Kretzschmar, M Michael, M DiBartolomeo, MA Mazier, et al. 2009. “Safety and Efficacy of First-line Bevacizumab with FOLFOX, XELOX, FOLFIRI and Fluoropyrimidines in Metastatic Colorectal Cancer: The BEAT Study.” Annals of Oncology 20 (11): 1842–1847.
Chicago author-date (all authors)
Van Cutsem, E, F Rivera, S Berry, A Kretzschmar, M Michael, M DiBartolomeo, MA Mazier, JL Canon, V Georgoulias, Marc Peeters, J Bridgewater, and D Cunningham. 2009. “Safety and Efficacy of First-line Bevacizumab with FOLFOX, XELOX, FOLFIRI and Fluoropyrimidines in Metastatic Colorectal Cancer: The BEAT Study.” Annals of Oncology 20 (11): 1842–1847.
Vancouver
1.
Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. ANNALS OF ONCOLOGY. OXFORD: Oxford University Press; 2009;20(11):1842–7.
IEEE
[1]
E. Van Cutsem et al., “Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study,” ANNALS OF ONCOLOGY, vol. 20, no. 11, pp. 1842–1847, 2009.
@article{862660,
  author       = {Van Cutsem, E and Rivera, F and Berry, S and Kretzschmar, A and Michael, M and DiBartolomeo, M and Mazier, MA and Canon, JL and Georgoulias, V and Peeters, Marc and Bridgewater, J and Cunningham, D},
  issn         = {0923-7534},
  journal      = {ANNALS OF ONCOLOGY},
  keywords     = {COMBINATION,THERAPY,OXALIPLATIN,LEUCOVORIN,FLUOROURACIL,TRIAL,PHASE-II},
  language     = {eng},
  number       = {11},
  pages        = {1842--1847},
  publisher    = {Oxford University Press},
  title        = {Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study},
  url          = {http://dx.doi.org/10.1093/annonc/mdp233},
  volume       = {20},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: